Afshin Shirkani

Afshin Shirkani

Auto-generated profile, based on publicly available information

Afshin Shirkani

Allergy and clinical Immunology Department, School of Medicine, Bushehr University of Medical Science, Bushehr, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
NHNicholas Hernandez
Nicholas Hernandez
GBGiorgia Bucciol
Giorgia Bucciol
LMLeen Moens
Leen Moens
JPJérémie Le Pen
Jérémie Le Pen
MSMohammad Shahrooei
Mohammad Shahrooei
XBXavier Bossuyt
Xavier Bossuyt
Vaccination against measles, mumps, and rubella (MMR) and yellow fever (YF) with live attenuated viruses can rarely cause life-threatening disease. Severe illness by MMR vaccines can be caused by inborn errors of type I and/or III interferon (IFN) immunity (mutations in IFNAR2, STAT1, or STAT2). Adverse reactions to the YF vaccine have remained unexplained. We report two otherwise healthy patients, a 9-yr-old boy in Iran with severe measles vaccine disease at 1 yr and a 14-yr-old girl in Brazil with viscerotropic disease caused by the YF vaccine at 12 yr. The Iranian patient is homozygous and the Brazilian patient compound heterozygous for loss-of-function IFNAR1 variations. Patient-derived fibroblasts are susceptible to viruses, including the YF and measles virus vaccine strains, in the absence or presence of exogenous type I IFN. The patients’ fibroblast phenotypes are rescued with WT IFNAR1. Autosomal recessive, complete IFNAR1 deficiency can result in life-threatening complications of vaccination with live attenuated measles and YF viruses in previously healthy individuals.

25 March 2014 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
AAAsghar Aghamohammadi
Asghar Aghamohammadi
PMPayam Mohammadinejad
Payam Mohammadinejad
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
BMBabak Mirminachi
Babak Mirminachi
MMMasoud Movahedi
Masoud Movahedi
NRNima Rezaei
Nima Rezaei

28 October 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
SKShaghayegh Khanmohammadi
Shaghayegh Khanmohammadi
NRNima Rezaei
Nima Rezaei
MKMehdi Khazaei
Mehdi Khazaei
ASAfshin Shirkani
Afshin Shirkani

9 September 2016 in Immunological Investigations
Verified
Journal Article
Closed access
ASAfshin Shirkani
Afshin Shirkani
MSMohammad Shahrooei
Mohammad Shahrooei
GAGholamreza Azizi
Gholamreza Azizi
HRHassan Rokni-Zadeh
Hassan Rokni-Zadeh
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAAsghar Aghamohammadi
Asghar Aghamohammadi
ZAP-70 deficiency is a rare autosomal recessive form of combined immunodeficiency (CID) characterized by selective absence of circulating CD8 T cells with low, normal, or increased CD4 T cells in peripheral blood. Up to now, 14 unique mutations in the ZAP70 gene have been identified in patients with ZAP-70-related CID. We present a 3-year-old boy with a history of recurrent bacterial infections and autoimmunity. Initial laboratory findings showed a normal total lymphocyte count, but low levels of CD8 and CD4 T cells and an abnormal lymphocyte proliferation response. Immunoglobulin levels were normal, but the specific antibody response was impaired. Whole exome sequencing revealed a mutation within the kinase domain of ZAP-70. ZAP-70 deficiency should be considered in infants and young children with recurrent bacterial infections, in spite of having palpable lymph nodes, a notable thymus shadow, and a normal total lymphocyte count.

20 November 2020 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
MSMaryam Zamani Sani
Maryam Zamani Sani
ABAfshar Bargahi
Afshar Bargahi
NMNiloofar Momenzadeh
Niloofar Momenzadeh
PDParva Dehghani
Parva Dehghani
MMMaryam Vakili Moghadam
Maryam Vakili Moghadam
MMMohsen Mohammadi
Mohsen Mohammadi

24 April 2023 in Biology
Verified
Journal Article
Open access
PDF file
NSniusha sharifinejad
niusha sharifinejad
GAGholamreza Azizi
Gholamreza Azizi
SRSeyed Erfan Rasouli
Seyed Erfan Rasouli
ZCZahra Chavoshzadeh
Zahra Chavoshzadeh
SMSeyed Alireza Mahdaviani
Seyed Alireza Mahdaviani
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
Cutaneous manifestations are one of the most common presentations among patients with inborn errors of immunity (IEI). These skin manifestations are often among the first presenting features in the majority of patients preceding the IEI diagnosis. We studied 521 available monogenic patients with IEI listed in the Iranian IEI registry up to November 2022. We extracted each patient’s demographic information, detailed clinical history of cutaneous manifestations, and immunologic evaluations. The patients were then categorized and compared based on their phenotypical classifications provided by the International Union of Immunological Societies. Most patients were categorized into syndromic combined immunodeficiency (25.1%), non-syndromic combined immunodeficiency (24.4%), predominantly antibody deficiency (20.7%), and diseases of immune dysregulation (20.5%). In total, 227 patients developed skin manifestations at a median (IQR) age of 2.0 (0.5–5.2) years; a total of 66 (40.7%) of these patients initially presented with these manifestations. Patients with cutaneous involvement were generally older at the time of diagnosis [5.0 (1.6–8.0) vs. 3.0 (1.0–7.0) years; p = 0.022]. Consanguinity was more common among patients who developed skin disorders (81.4% vs. 65.2%, p < 0.001). The overall skin infection rate and the type of dominant pathogens were significantly different among the IEI patients in different phenotypical classifications (p < 0.001). Atopic presentation, including urticaria, was highly prevalent among patients with congenital defects of phagocytes (p = 0.020). The frequency of eczema was also significantly higher among cases with both syndromic and non-syndromic combined immunodeficiency (p = 0.009). In contrast, autoimmune cutaneous manifestations, including alopecia and psoriasis, were most common in patients with immune dysregulation (p = 0.001) and defects in intrinsic or innate immunity (p = 0.031), respectively. The presence of autoimmune cutaneous complications significantly improved the survival rate of IEI patients (p = 0.21). In conclusion, cutaneous manifestations were observed in nearly 44% of Iranian patients with monogenic IEI. A considerable number of patients with cutaneous involvements developed these disorders as their first manifestation of the disease, which was particularly noticeable in patients with non-syndromic combined immunodeficiency and phagocytic defects. The neglected skin disorders in IEI patients might delay diagnosis, which is generally established within a 3-year interval from the development of skin-related problems. Cutaneous disorders, especially autoimmune features, might indicate a mild prognosis in IEI patients.